Last reviewed · How we verify
Memantine Hydrochloride Tablets
Memantine is an uncompetitive antagonist of the N-methyl-D-aspartate (NMDA) receptor that reduces excessive glutamate-mediated neuronal excitotoxicity.
Memantine is an uncompetitive antagonist of the N-methyl-D-aspartate (NMDA) receptor that reduces excessive glutamate-mediated neuronal excitotoxicity. Used for Moderate to severe Alzheimer's disease.
At a glance
| Generic name | Memantine Hydrochloride Tablets |
|---|---|
| Sponsor | University of Virginia |
| Drug class | NMDA receptor antagonist |
| Target | NMDA receptor |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | FDA-approved |
Mechanism of action
Memantine blocks the NMDA receptor ion channel in a use-dependent manner, allowing it to preferentially inhibit pathological overactivation of glutamate signaling while preserving normal synaptic transmission. This mechanism protects neurons from excitotoxic damage associated with neurodegenerative conditions. The drug is thought to restore the balance of neuronal activity disrupted in Alzheimer's disease and other cognitive disorders.
Approved indications
- Moderate to severe Alzheimer's disease
- Mild to moderate Alzheimer's disease (in combination with cholinesterase inhibitors)
Common side effects
- Dizziness
- Headache
- Confusion
- Constipation
- Hypertension
- Fatigue
Key clinical trials
- Motor Neurone Disease - Systematic Multi-Arm Adaptive Randomised Trial (PHASE2, PHASE3)
- Memantine for the Treatment of Social Deficits in Youth With Disorders of Impaired Social Interactions (PHASE3)
- Satisfaction With Orodispersible vs Conventional Memantine in Moderate to Severe Alzheimer's Disease (PHASE4)
- The Use of Memantine for Prevention of Alzheimer's Disease (PHASE2)
- Evaluating the Neurophysiologic and Clinical Effects of Single Dose Drug Challenge (PHASE2)
- Efficacy and Safety of DMB-I (INN: Latrepirdine) in Patients With Alzheimer Type Dementia (PHASE3)
- Efficacy and Safety of memanTine in the Treatment Of Frequently symPtomatic Atrial Premature Beats (PHASE2)
- Treatment of Orthostatic Intolerance (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Memantine Hydrochloride Tablets CI brief — competitive landscape report
- Memantine Hydrochloride Tablets updates RSS · CI watch RSS
- University of Virginia portfolio CI